Results 261 to 270 of about 3,758,136 (300)
Some of the next articles are maybe not open access.
Nonsteroidal Anti-Inflammatory Drug Enteropathy
Gastrointestinal Endoscopy Clinics of North America, 1999Although the upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs( NSAID) is well documented, the appreciation that NSAID damage extends beyond the duodenum is less well recognized. Recent data suggests that clinically important ulceration can be found in the small intestine, and may lead to complications such as obscure bleeding ...
openaire +2 more sources
Chirality and Nonsteroidal Anti-Inflammatory Drugs
Drugs, 1996The nonsteroidal anti-inflammatory drugs (NSAIDs) are of significant clinical importance and include congeners of many chemical classes, some of which incorporate an asymmetric or chiral carbon atom. With very few exceptions, chiral NSAIDs have been marketed for clinical use as racemates. However, it is apparent that differences, sometimes major, exist
openaire +2 more sources
Nonsteroidal Anti-Inflammatory Drug Gastropathy
Gastrointestinal Endoscopy Clinics of North America, 1996NSAID gastropathy is characterized by subepithelial hemorrhages, erosions, and ulcers. Approximately half of patients taking NSAIDs regularly have gastric erosions and 10% to 30% have gastric ulcers. Although gastric lesions are common at endoscopy, clinically significant problems are uncommon.
openaire +2 more sources
Toxicity of Nonsteroidal Anti-inflammatory Drugs
Archives of Internal Medicine, 1987The literature on toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs) is confusing. Much of the data relied on by pharmaceutical companies and the Food and Drug Administration comes from so-called Phase Three Trials . These are double-blind, controlled trials, usually of relatively brief (three months or less) duration.
openaire +2 more sources
Toxicities of the nonsteroidal anti-inflammatory drugs
Current Opinion in Rheumatology, 1992There has been significant progress in defining the risks associated with the use of nonsteroidal anti-inflammatory drugs. There is now clear consensus that certain patient subsets are at an increased risk for gastroduodenal mucosal damage when those patients are treated with these drugs.
openaire +2 more sources
Nonsteroidal Anti-inflammatory Drugs
Pharmacology, 2008Satish K. Srivastava, Kota V. Ramana
openaire +3 more sources
Nonsteroidal anti-inflammatory drugs and antihypertensives
The American Journal of Medicine, 1991Approximately 60 million people in the United States have hypertension (BP greater than or equal to 140/90 mm Hg), 40 million have arthritis clinically suitable for nonsteroidal anti-inflammatory drug (NSAID) therapy, and millions take NSAIDs for nonarthritic conditions, creating considerable potential for concomitant administration of NSAIDs and ...
openaire +2 more sources
Nonsteroidal anti-inflammatory drug toxicity
Current Opinion in Rheumatology, 1993The nonsteroidal anti-inflammatory drugs continue to be a mainstay of therapy for patients with chronic pain and inflammation. Because large numbers of these drugs are prescribed, even the most unusual adverse reactions are not uncommon. During the past year several reviews have appeared on the problems of nonsteroidal anti-inflammatory drug-induced ...
openaire +2 more sources
Nonsteroidal anti-inflammatory drugs and the kidney
Current Opinion in Nephrology and Hypertension, 2001T, Stürmer +2 more
openaire +2 more sources
Nonsteroidal Anti-Inflammatory Drug Risks
The Journal of the American Dental Association, 2020Allan C, Jones, Parish P, Sedghizadeh
openaire +2 more sources